LifeMD (LFMD) Scheduled to Post Quarterly Earnings on Thursday

LifeMD (NASDAQ:LFMD) will issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. LifeMD has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The company had revenue of $50.66 million during the quarter, compared to analysts’ expectations of $48.47 million. During the same quarter in the previous year, the company earned ($0.23) earnings per share. On average, analysts expect LifeMD to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeMD Price Performance

Shares of NASDAQ LFMD opened at $4.15 on Thursday. The company has a debt-to-equity ratio of 10.83, a quick ratio of 0.83 and a current ratio of 0.87. LifeMD has a one year low of $3.99 and a one year high of $12.88. The firm has a market capitalization of $178.74 million, a P/E ratio of -5.93 and a beta of 1.18. The company’s fifty day moving average is $4.89 and its two-hundred day moving average is $6.81.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. KeyCorp lowered their target price on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 price objective on shares of LifeMD in a research note on Friday, September 20th. Finally, B. Riley began coverage on LifeMD in a research report on Friday, August 23rd. They set a “buy” rating and a $11.00 target price on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.